Tabelecleucel

Lymphoproliferative Syndrome

Pierre Fabre MedicamentCell therapyPhase 3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

26 Active assets in the Lymphoproliferative Syndrome cohort.

Asset / Sponsor	Phase	Rating
Darbepoetin Alfa Mayo Clinic	Phase 3	BB
Epoetin Alfa Mayo Clinic	Phase 3	BB
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd.	Phase 2	BB
Sodium Ferric Gluconate Mayo Clinic	Phase 3	BB
Amitriptyline Alliance for Clinical Trials in Oncology	Phase 3	BB

View all 48 →

Same molecule, other indications

Tabelecleucel is also rated in:

Epstein-Barr virus-associated lymphoproliferative disorderActive

BB

Indicative · Phase 3

66 / 100

disease related to hematopoietic stem cell transplantActive

BB

Indicative · Phase 3

66 / 100

Epstein-Barr virus-related tumorDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.